Back to Search Start Over

Blocking tumor-platelet crosstalk to prevent tumor metastasis via reprograming glycolysis using biomimetic membrane-hybridized liposomes.

Authors :
Zhu, Jie
Wang, Rui
Yang, Chenxiao
Shao, Xinyue
Zhang, Yi
Hou, Jiazhen
Gao, Yanrong
Ou, Ante
Chen, Meiwan
Huang, Yongzhuo
Source :
Journal of Controlled Release. Feb2024, Vol. 366, p328-341. 14p.
Publication Year :
2024

Abstract

Activated platelets promote tumor progression and metastasis through active interactions with cancer cells, especially in promoting epithelial-mesenchymal transition (EMT) of tumor cells and shedding tumor cells into the blood. Blocking platelet-tumor cell interactions can be a potential strategy to inhibit tumor metastasis. Platelet activation requires energy produced from aerobic glycolysis. Based on this, we propose a platelet suppression strategy by reprogramming glucose metabolism of platelets, which has an advantage over conventional antiplatelet treatment that has a risk of serious hemorrhage. We develop a biomimetic delivery system using platelet membrane-hybridized liposomes (PM-Lipo) for codelivery of quercetin and shikonin to simultaneously inhibit lactate transporter MCT-4 and a glycolytic enzyme PKM2 for achieving metabolic reprogramming of platelets and suppressing platelet activation. Notably, PM-Lipo can also inhibit glycolysis in cancer cells, which actually takes "two-birds-one-stone" action. Consequently, the platelet-tumor cell interactions are inhibited. Moreover, PM-Lipo can bind with circulating tumor cells and reduce their seeding in the premetastatic microenvironment. The in vivo studies further demonstrated that PM-Lipo can effectively suppress primary tumor growth and reduce lung metastasis without affecting inherited functions of platelets. Reprogramming glycolysis of platelets can remodel the tumor immune microenvironment, including suppression of Treg and stimulation of CTLs. After i.v. injection, PM-Lipo arrives at the tumor site and acts on platelets and tumor cells. By reprogramming glycolysis in both of them, PM-Lipo inhibits platelet activation and tumor cell proliferation, blocks tumor-platelet interaction, and suppresses tumor metastasis. Additionally, PM-Lipo can bind with circulating tumor cells and reduce their seeding in pre-metastatic niche. [Display omitted] [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01683659
Volume :
366
Database :
Academic Search Index
Journal :
Journal of Controlled Release
Publication Type :
Academic Journal
Accession number :
175768994
Full Text :
https://doi.org/10.1016/j.jconrel.2023.12.052